Your browser doesn't support javascript.
Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital.
Costa, Cristina; Scozzari, Gitana; Migliore, Enrica; Galassi, Claudia; Ciccone, Giovannino; Ricciardelli, Guido; Scarmozzino, Antonio; Angelone, Lorenzo; Cassoni, Paola; Cavallo, Rossana.
  • Costa C; Microbiology and Virology Unit, University Hospital Città Della Salute e Della Scienza di Torino, 10126 Turin, Italy.
  • Scozzari G; Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
  • Migliore E; Molinette Hospital Medical Direction, University Hospital Città Della Salute e Della Scienza di Torino, 10126 Turin, Italy.
  • Galassi C; Clinical Epidemiology Unit, University Hospital Città Della Salute e Della Scienza di Torino and CPO Piemonte, 10126 Turin, Italy.
  • Ciccone G; Clinical Epidemiology Unit, University Hospital Città Della Salute e Della Scienza di Torino and CPO Piemonte, 10126 Turin, Italy.
  • Ricciardelli G; Clinical Epidemiology Unit, University Hospital Città Della Salute e Della Scienza di Torino and CPO Piemonte, 10126 Turin, Italy.
  • Scarmozzino A; Microbiology and Virology Unit, University Hospital Città Della Salute e Della Scienza di Torino, 10126 Turin, Italy.
  • Angelone L; Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
  • Cassoni P; Molinette Hospital Medical Direction, University Hospital Città Della Salute e Della Scienza di Torino, 10126 Turin, Italy.
  • Cavallo R; Molinette Hospital Medical Direction, University Hospital Città Della Salute e Della Scienza di Torino, 10126 Turin, Italy.
  • On Behalf Of The Collaborative Group; Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Vaccines (Basel) ; 10(7)2022 Jun 27.
Article in English | MEDLINE | ID: covidwho-1911728
ABSTRACT
We describe the results of a T-cell immunity evaluation performed after a median elapsed time of 7 months from second-dose BNT162b2 vaccine administration, in a representative sample of 419 subjects from a large cohort of hospital workers. Overall, the Quantiferon SARS-CoV-2 assay detected a responsive pattern in 49.9%, 59.2% and 68.3% of subjects to three different antigenic stimuli from SARS-CoV-2, respectively, with 72.3% of positivity to at least one antigenic stimulus. Potential predictors of cellular response were explored by multivariable analyses; factors associated with positivity to cellular response (to Ag1 antigenic stimulus) were a previous SARS-CoV-2 infection (OR = 4.24, 95% CI 2.34-7.67, p < 0.001), increasing age (per year OR = 1.03 95% CI 1.01-1.06, p = 0.019 and currently smoking (compared to never smoking) (OR = 1.93, 95% CI 1.11-3.36, p = 0.010). Increasing time interval between vaccine administration and T-cell test was associated with decreasing cellular response (per week of time OR = 0.94, 95% CI 0.91-0.98, p = 0.003). A blood group A/AB/B (compared to group O) was associated with higher levels of cellular immunity, especially when measured as Ag2 antigenic stimulus. Levels of cellular immunity tended to be lower among subjects that self-reported an autoimmune disorder or an immunodeficiency and among males. Further studies to assess the protective significance of different serological and cellular responses to the vaccine toward the risk of reinfection and the severity of COVID-19 are needed to better understand these findings.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10071031

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10071031